Ubs Asset Management Americas Inc Celldex Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 213,846 shares of CLDX stock, worth $5.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
213,846
Previous 131,296
62.87%
Holding current value
$5.56 Million
Previous $2.38 Million
82.58%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CLDX
# of Institutions
203Shares Held
68.3MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$159 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$136 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$122 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$103 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$99.3 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.22B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...